Helicase-primase inhibitors for herpes simplex virus: looking to the future of non-nucleoside inhibitors for treating herpes virus infections

Biswas, Subhajit and Sukla, Soumi and Field, Hugh J. (2014) Helicase-primase inhibitors for herpes simplex virus: looking to the future of non-nucleoside inhibitors for treating herpes virus infections. Future Medicinal Chemistry, 6 (1). pp. 45-55. ISSN 1756-8919

Full content URL: http://dx.doi.org/10.4155/fmc.13.192

Full text not available from this repository.

Item Type:Article
Item Status:Live Archive

Abstract

Helicase-primase inhibitors (HPIs) are the first new family of potent herpes virus (herpes simplex and varicella-zoster virus) inhibitors to go beyond the preliminary stages of investigation since the emergence of the original nucleoside analog inhibitors. To consider the clinical future of HPIs, this review puts the exciting new findings with two HPIs, amenamevir and pritelivir, into the historical context of antiviral development for the prevention and treatment of herpes simplex virus over the last century and, on this basis, the authors speculate on the potential evolution of these and other non-nucleoside inhibitors in the future.

Keywords:pritelivir, amenamevir, antiviral, mutant, drug-resistance, NotOAChecked
Subjects:B Subjects allied to Medicine > B210 Pharmacology
C Biological Sciences > C540 Virology
A Medicine and Dentistry > A300 Clinical Medicine
C Biological Sciences > C741 Medical Biochemistry
Divisions:College of Science > School of Life Sciences
Related URLs:
ID Code:12798
Deposited On:31 Dec 2013 13:41

Repository Staff Only: item control page